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ABSTRACT
Introduction: Gastrointestinal symptoms are
common among patients with transthyretin
familial amyloid polyneuropathy (TTR-FAP).
This post hoc analysis evaluated the
nutritional status of TTR-FAP patients treated
with tafamidis while enrolled in clinical trials.
Methods: Nutritional status was measured by
the modified body mass index
(mBMI = BMI 9 albumin level). Treatment-
related changes in mBMI were reported for 71
Val30Met TTR-FAP patients who completed an
18-month, randomized, double-blind, placebo-
controlled trial and who continued into its
open-label, 12-month extension.
Results: At month 18, mBMI worsened in the
placebo group (n = 33) (-33 ± 16 kg/m2 g/l,
P = 0.04 versus baseline) but improved in the
tafamidis group (n = 38) (?37 ± 14 kg/m2 g/l,
P = 0.01 versus baseline) such that the effect
size between the groups was statistically
significant (P = 0.001). By month 30
(completion of the open-label extension),
placebo patients with 12 months of tafamidis
treatment and tafamidis-treated patients with
30 months of treatment both tended to increase
their mBMI (28 ± 19 kg/m2 g/l and 16 ± 18 kg/
m2 g/l, respectively). Increase in BMI was most
pronounced in patients with low BMI at entry
into the studies.
Conclusions: mBMI is well suited to monitor
disease progression in TTR-FAP patients. The
Trial registration: These data were derived from two
trials registered at clinicaltrials.gov as NCT00409175 and
NCT00791492.
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delay in neurological deterioration brought
about by tafamidis treatment in clinical trials
is associated with improvements in, or
maintenance of, mBMI.
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INTRODUCTION
Transthyretin familial amyloid polyneuropathy
(TTR-FAP) is the most common phenotypic
presentation of the TTR amyloidoses, a group
of fatal autosomal dominant disorders of
variable penetrance caused by mutated TTR
that facilitates dissociation of TTR tetramers
into amyloidogenic misfolded TTR and
subsequent assembly into TTR amyloid which
deposits into various organs [1]. The particularly
affected anatomical structures are the
peripheral and autonomic nerves, heart,
gastrointestinal tract, kidneys, eyes, and
connective tissue of the carpal ligament [1, 2].
Worldwide, [100 point mutations of the TTR
gene located on chromosome 18q12.1 have
been described, nearly all of which can lead to
amyloidosis [3]. The vast majority of TTR-FAP
cases (85%) are associated with replacement of
valine by methionine at position 30 of the
protein (Val30Met) [1, 3, 4].
The hallmark of TTR-FAP is
neurodegeneration of sensory, motor, and
autonomic nerve fibers [1]. Gastrointestinal
features are prominent in most cases, vary
considerably in type and severity both within
and between TTR mutations, and may present
before the onset of peripheral polyneuropathy
[5]. Weight loss, nausea, and alternating bouts
of constipation and diarrhea are common
during early-stage disease, while
malabsorption, severe chronic diarrhea, and
cachexia often occur during late-stage disease
[5–10]. Severe malnutrition and opportunistic
infections lead to death in these late-stage
patients [10, 11].
Body mass index (BMI) is a suboptimal
measure to assess the clinical status of patients
affected by the wasting characteristic of TTR-
FAP since high BMI values can be observed in
edematous malnourished patients due to low
serum albumin. Modified BMI (mBMI) (the
product of BMI and serum albumin) corrects
for the effect of hypoalbuminemia and is a
better reflection of overall nutritional health. In
clinical practice, mBMI is an effective tool for
monitoring TTR-FAP progression as it is closely
related to time before death, duration of
gastrointestinal disturbances, malabsorption,
functional capacity, and survival after liver
transplant [11, 12]. Furthermore, mBMI reports
on hepatic synthetic capacity, and on
neurogenic and absorptive gastrointestinal
functions. As such, mBMI should be
considered an integrative physiologic indicator
for patients with TTR-FAP.
Tafamidis is a once-daily, orally bioavailable,
pharmacological chaperone and kinetic
stabilizer of TTR approved for the treatment of
adult patients with TTR-FAP in several countries
[13, 14]. Tafamidis binds with high affinity and
selectivity to patient-derived wild-type TTR and
to most amyloidogenic TTR variants capable of
forming tetramers, including the Val30Met TTR
variant [13]. In a randomized, placebo-
controlled trial (Fx-005, NCT00409175) of
patients with Val30Met TTR-FAP [15],
tafamidis was well tolerated and associated
with slowing the progression of peripheral
neurologic impairment and was better at
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preserving quality of life versus placebo [15].
One of the other multiple outcome measures
used to evaluate the efficacy of tafamidis was
nutritional status at 18 months, which
improved in the tafamidis group but worsened
in the placebo group [15]. Furthermore, the
deterioration in mBMI observed among
placebo-treated patients in this study was
reversed by tafamidis during this study’s
12-month open-label extension phase [16].
Given the prominent role that nutrition
plays in TTR-FAP progression, the objective of
the present post hoc analysis was to present a
more detailed account of the effects of tafamidis
on nutritional status as measured by mBMI and
its components in patients with TTR-FAP who
participated in these clinical trials.
METHODS
Patients and Study Designs
The full methodologies of the two international
multicenter trials (ClinicalTrials.gov: Fx-005,
NCT00409175; Fx-006, NCT00791492) have
been published previously [15, 16]. Eligible
patients in the Phase IIb, randomized,
controlled trial were consenting men and
women aged 18–75 years with a documented
Val30Met TTR mutation and symptomatic,
biopsy-confirmed TTR amyloidosis. Patients
were randomly assigned in a 1:1 ratio to either
oral tafamidis 20 mg or placebo once daily for
18 months, and completers were subsequently
eligible to enroll in the single-arm extension
study and receive the same tafamidis dosage
regimen for 12 months [16]. Thus, there were
two treatment sequence groups in the extension
study: patients randomized to 18 months of
tafamidis who continued to receive tafamidis
(tafamidis–tafamidis) and patients randomized
to 18 months of placebo who were switched to
tafamidis (placebo–tafamidis). Although
patients and investigators were aware that all
patients were receiving tafamidis during the
extension study they remained blinded to the
treatment assignment in the randomized phase.
Compliance with Ethics
Both study protocols were approved by the local
scientific ethical committees and regulatory
authorities, and conducted in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008 [17]. Informed consent was
obtained from all patients for being included
in the study.
Clinical Assessment
In both studies, mBMI was calculated as the
product of the BMI and serum albumin
concentration. Height, weight, and albumin
were measured during the baseline visit, and
weight and serum albumin were measured
during each follow-up visit (every 6 months
during treatment) up to and including the
month 30 end-of-treatment visit.
Analysis Populations
A longitudinal mBMI analysis was conducted
on the intent-to-treat (ITT) population of the
extension study, defined as those patients who
completed the randomized, controlled study
per-protocol, enrolled in the extension phase,
and received at least one dose of study
medication without an interruption of
[2 months between the two studies.
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Statistical Analysis
All efficacy data analyses were performed using
descriptive statistics (mean ± standard
deviation for baseline parameters and least
squares mean ± standard error for on-
treatment comparisons) using SAS version
9.1.3 (SAS Institute Inc., Cary, North
Carolina, USA). For each efficacy measure,
change from baseline to each treatment time
point was analyzed using a repeated measures
mixed model analysis of variance for between-
group comparisons. The model used an
unstructured covariance matrix; with
treatment group and treatment group-by-
month interaction as fixed effects, and subject
as a random effect. Within-group comparisons
were performed using paired t tests.
To examine possible differential effects of
baseline BMI on change from baseline,
categorical analyses stratified by baseline BMI
strata [BMI \20 kg/m2 (underweight), BMI
20–25 kg/m2 (normal), BMI [25 kg/m2
(overweight)] were performed. Treatment
group comparisons and differences between
BMI strata at each visit were analyzed using
repeated measures mixed models with change
from baseline as the dependent variable, and
treatment, baseline BMI strata, and treatment-
by-BMI strata as fixed effects.
RESULTS
Patient Disposition
The flow of patients through the randomized,
controlled study and its extension phase has
been described previously and is summarized in
Fig. 1 [15, 16]. The salient observation was the
large proportion of patients who discontinued
randomized treatment due to availability of a
donor liver rather than due to any study-related
cause. As a result, of the 125 patients (64 treated
with tafamidis and 61 treated with placebo)
who constituted the ITT population of the
randomized, controlled study, only 47 and 44
patients in the tafamidis and placebo group,
respectively, completed the trial. Of these 91
patients, 86 patients (94%) agreed to enroll in
the extension study and all but one patient
received at least one dose of tafamidis. Fourteen
patients had treatment with tafamidis
interrupted for at least 2 months between
studies and were excluded from the analysis
population, as was one patient who
discontinued due to availability of a donor
liver, leaving 71 patients in the ITT population
of the extension study (38 treated with
tafamidis and 33 treated with placebo). This
treatment interruption was due to a delay in
regulatory approval at two South American sites
and one site in Portugal.
Baseline Demographics and Clinical
Characteristics
The medical histories of the extension study’s
ITT population at the baseline of the
randomized, controlled trial were
representative of an early-stage TTR-FAP
population: nearly all patients ([90%)
reported nervous system disorders, most
reported gastrointestinal symptoms ([70%),
mean values for serum albumin, BMI, and
mBMI were normal; nutritional status was
well-preserved; and there was modest
impairment of Neuropathy Impairment Score-
Lower Limbs (NIS-LL) and Norfolk Quality of
Life-Diabetic Neuropathy total quality of life
score (Table 1) [18–21]. There were no obvious
differences in demographics or clinical
characteristics, including nutritional health,
between the tafamidis and placebo groups at
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baseline. At least half of the subjects had disease
onset prior to their fifth decade (i.e., early-onset
Val30Met TTR-FAP). Recipients of placebo
exhibited worse neurological impairment and
nutritional health at the start of the open-label
extension compared with patients who had
been treated with tafamidis. Six of 85 patients
(7%) had a medical history of peripheral edema.
mBMI
Figure 2a shows that, over the 18-month,
randomized, treatment period, placebo
recipients experienced a worsening in mBMI at
each on-treatment study visit from
1,020 ± 244 kg/m2 g/l yielding a change from
baseline to month 18 of -33 ± 16 (P = 0.04). In
contrast, over the same time period, patients
treated with tafamidis experienced an
improvement in mBMI at each on-treatment
study visit (from 1,032 ± 167 kg/m2 g/l to give a
change from baseline to month 18 of ?37 ± 14,
P = 0.01). This represents an adjusted least
squares mean difference of 73 ± 21 kg/m2 g/l
between the tafamidis and placebo groups
(P = 0.001).
This between-group difference widened
slightly when patients entered the extension
phase but statistical significance was lost
because the sample size had decreased relative
Fig. 1 Patient disposition in the randomized, controlled trial and its 12-month open-label extension. AE adverse event, ITT
intention to treat, ITT-OC ITT-observed cases
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to month 18 of the randomized controlled trial:
patients who were originally randomized to
placebo had a mean baseline mBMI value of
990 ± 265 kg/m2 g/l compared with
1,068 ± 142 kg/m2 g/l in patients originally
randomized to tafamidis (P = 0.08). Once
placebo patients commenced treatment with
tafamidis, the worsening in mean mBMI
observed during the 18-month placebo phase
was reversed during the open-label, 12-month,
extension phase (Fig. 2a). At the conclusion of
the open-label extension study, the patients in
the placebo treatment group had a change from
baseline increase in mBMI of 28 ± 19 kg/m2 g/l
while the tafamidis patients had an mBMI
increase of 16 ± 18 kg/m2 g/l, there being no
statistically significant difference between the
two groups (P = 0.64). mBMI changes from
baseline to month 18 were highly comparable
across the study centers, with the tafamidis
groups having a mean gain in mBMI at every
study center, whereas the placebo groups had a






Median age, years (range) 36.5 (25 to 74) 34.0 (23 to 71)
Female, n (%) 21 (55) 18 (54)
Caucasian, n (%) 37 (97) 33 (100)
Median duration of TTR-FAP symptoms, months (range) 17.5 (3 to 268) 18.0 (2 to 133)
Mean height, m (SD) 1.66 (0.1) 1.67 (0.1)
Mean weight, kg (SD) 65.1 (12.4) 64.4 (14.4)
66.2 (11.9)a 63.3 (14.1)a
Mean serum albumin, g/l (SD) 43.9 (3.5) 44.2 (4.2)
44.7 (3.4)a 43.1 (4.0)a
Mean BMI, kg/m2 (SD) 23.6 (3.6) 23.1 (5.2)
23.9 (3.0)a 22.7 (5.2)a
Mean mBMI, kg/m2 g/l (SD) 1,031.6 (166.5) 1,020.2 (244.3)
1,068.4 (142.4)a 990.1 (265.0)a
NIS-LL (range 0–88)
Mean (SD) 6.8 (10.0) 11.6 (14.5)
Median (range) 4.0 (0 to 49) 6.0 (2 to 57)
TQOL, median (range) 14 (-1 to 110) 17 (0 to 107)
11 (-1 to 97)a 28 (-1 to 96)a
BMI body mass index, ITT intent-to-treat, NIS-LL Neuropathy Impairment Score-Lower Limbs, SD standard deviation,
TQOL Norfolk Quality of Life-Diabetic Neuropathy total quality of life, TTR-FAP transthyretin familial amyloid
polyneuropathy
a At baseline of the open-label extension study
106 Neurol Ther (2014) 3:101–112
mean mBMI loss at every study center (Pfizer
Inc., data on file).
The reversal of mean mBMI decrements
observed after patients switched from placebo
to tafamidis in the extension study manifested
because of improvements in both components
of the mBMI (BMI and serum albumin level)
during the tafamidis treatment phase (Fig. 2b,
c).
To examine the effect of initial BMI on
changes from baseline in BMI, the patients
were divided into three groups based on
baseline BMI: underweight (BMI \20 kg/m2),
normal (BMI between 20 kg/m2 and 25 kg/m2),
or overweight (BMI [25 kg/m2). Tafamidis
patients who were underweight initially
gained in BMI during the study period to
month 18 (1.5 ± 0.6 kg/m2) (Fig. 3). Smaller
gains were observed in the normal BMI group
(0.5 ± 0.3 kg/m2), whereas a decrease in BMI
was observed in patients in the overweight BMI
group (-0.5 ± 0.4 kg/m2). For patients in the
placebo group, the BMI was relatively constant
during the observation period, again with a
tendency for increased loss in the overweight
group at month 18. In the tafamidis–tafamidis
treatment sequence group at month 30,
patients who were underweight or normal at
baseline showed moderate increases in BMI
(underweight, 0.6 ± 0.9 kg/m2; normal,
0.5 ± 0.4 kg/m2); while the patients in the
overweight group showed moderate decreases
in BMI (-0.4 ± 0.6 kg/m2). In the placebo-
tafamidis treatment sequence group at month
Fig. 2 Changes in mBMI (a), BMI (b), and albumin
(c) in the randomized, controlled trial and its open-label
extension. BMI body mass index, LS least squares, mBMI
modiﬁed BMI, SE standard error, TTR-FAP transthyretin
familial amyloid polyneuropathy
b
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30, underweight patients remained at their pre-
randomization BMI. The patients in the normal
baseline group showed a moderate increase in
BMI at month 30 (0.8 ± 0.6 kg/m2), whereas the
patients in the overweight group showed a
small decrease in BMI (-0.1 ± 0.5 kg/m2).
DISCUSSION
This was a post hoc analysis of two
interventional studies involving patients with
Val30Met TTR-FAP. The main finding is the
improvement in, or maintenance of, nutritional
status associated with tafamidis treatment in
these patients. Particularly noteworthy was the
reversal of decline in mBMI observed in the
placebo group following the switch to tafamidis
in the extension study. The Val30Met TTR-FAP
patients under study had early-stage disease,
with preserved nutritional status as evidenced
by the participation of overweight individuals.
It was therefore not expected, or desired, that
BMI would steadily increase during the
tafamidis treatment period. An interesting
finding was that the BMI increase associated
with tafamidis was largely confined to those
with relatively low values in whom an
improvement is desired.
The patients summarized in this analysis are
only those who continued into the open-label
extension (i.e., within 2 months of completing
the randomized trial) and received at least one
dose of tafamidis. While selection bias may
have been introduced into the ITT population
of the extension study due to loss of the
randomization process, the authors believe
that the degree of selection bias is minor as
the tafamidis and placebo groups were matched
regarding demographics and clinical
characteristics at baseline, and most patients
discontinued the randomized, controlled trial
to obtain liver transplants. It should be further
noted that the studies were short relative to the
duration of disease. Nevertheless, our findings
that tafamidis was associated with maintaining
or improving mBMI over a 2.5-year period in
Fig. 3 BMI change from baseline to on-treatment timepoints. BMI body mass index, LS least squares, SE standard error,
TTR-FAP transthyretin familial amyloid polyneuropathy
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patients with Val30Met TTR-FAP, as well as
exerting the most beneficial effects on BMI in
underweight patients, underscore the
importance of detecting and treating TTR-FAP
promptly. This enables patients with early-stage
disease to obtain the benefits of therapy while
they still have the physiologic capacity to
recover and maintain some of their nutritional
health. In a single-center, non-randomized,
controlled trial conducted in France of 37
consecutive patients with late-stage Val30Met
TTR-FAP, tafamidis was associated with
negligible efficacy on neurological function
and disability [22]. It could be argued that the
mBMI improvement observed is related to an
increased appetite and not related to tafamidis
efficacy; however, the finding of a more
pronounced effect on patients presenting with
low mBMIs makes such an assumption less
convincing. In addition, the nonsteroidal anti-
inflammatory drug (NSAID) diflunisal, which
also showed efficacy as a disease modifying
agent in a recent controlled trial [20], only had a
modest impact on mBMI. Nausea and dyspepsia
are common adverse effects of NSAIDs [21],
which may explain the more modest response
in mBMI among diflunisal recipients in the
trial.
In addition to the utility of mBMI as a
postsurgical outcome predictor [12, 23], this
simple and easy to use internal medicine tool
can be a reliable measure reflecting the clinical
course of TTR-FAP and treatment response.
Improvements in mBMI coincide with
improvements in neurologic function and
quality of life [15, 24], while deteriorating
mBMI is associated with disease progression
[11]. In Portuguese patients with Val30Met TTR-
FAP, weight loss preceded neurological and
gastrointestinal symptoms in a substantial
proportion of the patients [7]. Although data
from prospective, observational studies revealed
that patients with an mBMI \700 kg/m2 g/l
have lower survival rates than patients with
higher mBMIs after liver transplant [12, 23],
there is no absolute threshold value identifying
patients with a normal mBMI from those
without. In a cross-sectional observational
study, healthy volunteers had a mean mBMI
of 1,199 kg/m2 g/l, which was statistically
significantly higher than those of Portuguese
Val30Met TTR-FAP patients with stage 1 disease
(independent ambulation, n = 29; 1,031.9 kg/
m2 g/l), stage 2 disease (assistance required to
walk, n = 16; 886.4 kg/m2 g/l), and stage 3
disease (wheelchair bound or bedridden,
n = 16; 759.7 kg/m2 g/l) [25].
Further research is warranted to investigate
the biological effects of active amyloidogenesis
on gastrointestinal structure and function, as
well as any beneficial effects that tafamidis has
in attenuating this aspect of the disease
process. mBMI may shed some light on
gastrointestinal TTR amyloidosis etiology, as
there is a weak but significant negative
correlation between this measure and gastric
emptying (Spearman rank-order coefficient, -
0.218, P = 0.006) in patients with Val30Met
TTR-FAP [9]; it is reasonable to suggest that the
BMI component of mBMI would be negatively
impacted by the classic early-stage symptoms
of gastroparesis (i.e., nausea, vomiting, and
early satiety) [26]. The mechanisms by which
amyloidogenesis causes gastric retention have
yet to be elucidated but this problem is evident
in patients with normal sympathetic and
parasympathetic activity, and only weakly
correlated with autonomic neuropathy [9].
Both factors of the mBMI composite endpoint
(BMI and serum albumin level) are expected to
be negatively impacted by the late-stage
disease often associated with malabsorption.
Although depletion of neuroendocrine cells
along the gastrointestinal tract from the
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stomach to the colon was hypothesized to
engender gastrointestinal disturbances [27–29],
no improvement of gastrointestinal function
was found after liver transplant [30–32], even
when the endocrine cell count in the upper
part of the tract normalized [30]. Attention has
turned to the loss of interstitial pacemaker cells
of Cajal as a potential contributing factor
involved in TTR-FAP gastrointestinal
complications. The numbers of these
mesenchymal cells were depleted in the
gastric wall of 11 deceased Japanese patients
with Val30Met TTR-FAP and attendant
gastrointestinal complications, compared with
10 deceased non-TTR-FAP patients [33].
Interestingly, similarities between the
gastroenteropathies associated with TTR-FAP
and type 2 diabetes mellitus may be relevant.
Accumulation of advanced glycation end
products, which bind to enteric neurons and
cause decreased production of nitric oxide
synthase, leading to a delayed gastric
emptying in diabetics [34], has also been
observed in amyloid-rich tissues of TTR-FAP
patients [35]. The smooth muscle degeneration
and fibrosis contributing to the
gastroenteropathy of diabetes mellitus [34, 36,
37] also requires investigation in TTR-FAP.
CONCLUSION
The delay in neurological deterioration brought
about by tafamidis treatment in clinical trials of
patients with early-stage Val30Met TTR-FAP was
associated with changes in mBMI
measurements as a result of improvements in,
or maintenance of, weight and serum albumin
levels. mBMI is an integrative physiologic
indicator which is useful for monitoring
disease progression and treatment response in
patients with TTR-FAP.
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